PURPOSE: To investigate the efficacy of Yoga as antihypertensive therapy and identify moderators of the BP response to Yoga. METHODS: Database searches identified 44 controlled Yoga trials that involved adults ≥19 yr, yielding 49 interventions. Analyses followed random-effects assumptions. RESULTS: Participants (N=3,376) were middle-aged (48.2±16.1yr), overweight (27.3±3.8kg/m2) adults with prehypertension (systolic BP [SBP]/diastolic BP [DBP], 129.3±14.0/ 80.9±9.1mmHg). Yoga was practiced 3.9±3.1 sessions/wk for 61.0±22.0 min/session for 14.8±13.5 wk. Overall, Yoga elicited moderate reductions in SBP (d+=-0.48, 95%CIs: -0.63, -0.33; -4.3mmHg) and DBP (d+=-0.50, 95%CIs: -0.64. -0.35; -3.4mmHg) compared to control (ps<0.001). Yoga produced greater SBP reductions among: samples with hypertension (-11.8mmHg, k=13) than prehypertension (-6.6mmHg, k=20) and normal BP (-2.9mmHg, k=14, p=0.001); interventions located in India (-9.9mmHg, k=21) than non-India Asian (-7.0mmHg, k=9) and non-Asian (-4.2mmHg, k=17, p=0.012) countries; and interventions with the largest variance (i.e., standard error) in the BP response (-20.0mmHg, k=15) than moderate (-6.5mmHg, k=16) and small (-1.6mmHg, k=16, p=0.001). Yoga produced greater DBP reductions among: samples with hypertension (-10.2mmHg, k=5) than prehypertension (-5.4mmHg, k=14) and normal BP (-2.1mmHg, k=24, p<0.001); interventions located in India (-4.0mmHg, k=20) than non-India Asian (-2.3mmHg, k=8) and non-Asian (-0.8mmHg, k=15, p=0.019) countries; and samples that practiced Yoga with a balanced combination of breathing, postures, and meditation/relaxation (-5.8mmHg, k=25) than Yoga largely focused on a single practice (e.g., left nostril breathing) (-2.3mmHg, k=18, p=0.006). CONCLUSION: Overall, 60 min of Yoga practiced 4 sessions/wk lowered BP ~3-4mmHg among adults with prehypertension. Yoga reduced SBP/DBP ~12/10mmHg among adults with hypertension, reductions nearly double of those reported with aerobic exercise. Yet caution is warranted in the clinical translation of our findings until future controlled trials specifically designed to target BP confirm them.